Imugene Expands Share Capital for Licensing Deal
Company Announcements

Imugene Expands Share Capital for Licensing Deal

Imugene Limited (AU:IMU) has released an update.

Imugene Limited has announced the issuance of over 87 million ordinary shares to fulfill part of the deferred consideration for a licensing agreement with Precision Biosciences Inc. This strategic move, detailed in their recent ASX release, is aimed at bolstering the company’s immuno-oncology portfolio, which includes innovative therapies for cancer treatment. The shares were issued in accordance with legal requirements and the company asserts compliance with all necessary disclosure obligations.

For further insights into AU:IMU stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskImugene Limited Begins Innovative Cancer Trial
TipRanks Australian Auto-Generated NewsdeskImugene Launches Phase 1b Trial in Australia
TipRanks Australian Auto-Generated NewsdeskImugene Achieves Milestone in Cancer Treatment Trial
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App